How to Value Clinical-Stage Biotech Stocks

How to Value Clinical-Stage Biotech Stocks


Valuing biotech companies that lack an FDA- or EMA-approved product is a tricky endeavor, to put it mildly. So, to help shed some light on this complicated issue, we asked three of our healthcare contributors how they go about calculating a workable valuation metric for clinical-stage biotechnology companies.



from Biotech News